Advanced Filters
noise

Newton, Massachusetts Clinical Trials

A listing of Newton, Massachusetts clinical trials actively recruiting patient volunteers.

Found 2,400 clinical trials
A Alisha Roby, MBA

Improving Visual Field Deficits With Noninvasive Brain Stimulation

This is a randomized, pilot interventional study in participants with visual field deficit (VFD) caused by cortical lesion. Damage to the primary visual cortex (V1) causes a contra-lesional, homonymous loss of conscious vision termed hemianopsia, the loss of one half of the visual field. The goal of this project is …

18 - 80 years of age All Phase N/A
E Emily Haus-McCarthy, OTD, OTR/L

Evaluating Treatment of ADHD in Children with Down Syndrome

Children with Down syndrome (DS) have a 3-5 time greater prevalence of Attention Deficit Hyperactivity Disorder (ADHD) than typically developing (TD) children. Despite this higher risk of ADHD, rates of stimulant medication treatment are disproportionately low in children with DS+ADHD, even though stimulants are the most efficacious ADHD treatment and …

6 - 17 years of age All Phase 4
R Rebecca Paynter, MSN, RN

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with DLBCL who are scheduled to receive CD19-directed CAR T-cell therapy. The first phase of the study will be open label …

18 years of age All Phase 1/2
N Nolan Joyce

PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.

18 - 95 years of age All Phase N/A
D Dan Iosifescu, MD, MMSc

Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33

The purpose of this research study is to determine if application of near infrared energy to the forehead can change blood flow in the brains of people with depression. Near infrared energy is like light but is not visible to the human eye.

18 - 65 years of age All Phase N/A
K Kelly Faulk, MD

Venetoclax Basket Trial for High Risk Hematologic Malignancies

This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS/AML), and acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL). The names of the study drugs involved in this study …

1 - 40 years of age All Phase 1
J Jacqueline S. Garcia, MD

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes …

18 years of age All Phase 1/2

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: Palazestrant (OP-1250) in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: Palazestrant (OP-1250) …

18 years of age All Phase 1
S Sari Feldman

Low Dose IL-2 for the Treatment of Crohn's Disease

The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe crohn's disease.

12 - 80 years of age All Phase 1/2
T Theodore S. Hong, MD

Folfox+Irinotecan+Chemort In Esophageal Cancer

In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: \- Liposomal irinotecan

18 years of age All Phase 2

Simplify language using AI